BAYER AG S/ADR (BAYRY)
BAYRY moved a median of 0.00% 30 minutes after news, and -0.11% by the close. How BAYRY actually reacts to news — the realized, point-in-time move the market made, measured across 106 labeled events over the last three years with zero look-ahead.
BAYRY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.00% | 51% | 105 |
| 30-min | 0.00% | 49% | 106 |
| 60-min | -0.05% | 44% | 106 |
| to close | -0.11% | 43% | 106 |
| Middle 50% of BAYRY reactions | -0.19% to +0.31% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 106 |
Half of all BAYER AG S/ADR news events land between -0.19% and +0.31% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BAYRY reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 37 | +0.15% | 57% | +0.20% |
| Analyst downgrades | 28 | 0.00% | 46% | -0.10% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how BAYRY ranks against every other measured name →
That’s how BAYRY usually reacts — get an email when it moves on news →Email me when BAYRY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BAYRY's baseline. Nothing else.
Recent BAYRY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause | Press release | Business Wire | -0.04% | -0.54% | |
| Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting | Press release | Business Wire | -0.03% | +0.37% | |
| U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes | Press release | Business Wire | -0.04% | -0.54% | |
| Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States | Press release | Business Wire | +0.03% | +0.11% | |
| Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle | Press release | Business Wire | -0.08% | -3.19% | |
| MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option | Press release | Business Wire | +0.22% | -0.22% | |
| U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer | Press release | Business Wire | -0.28% | +0.35% | |
| Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes | Press release | Business Wire | +0.21% | -0.07% | |
| Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs | Press release | Business Wire | +0.21% | -0.07% | |
| Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road | Press release | Business Wire | +0.00% | -0.14% | |
| BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION | Press release | Business Wire | +0.21% | +0.42% | |
| U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer | Press release | Business Wire | +0.21% | -0.49% | |
| Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026 | Press release | Business Wire | -0.26% | +0.78% | |
| Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026 | Press release | Business Wire | +0.07% | -0.14% | |
| LYNKUET® (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer | Press release | Business Wire | +0.00% | -0.14% | |
| One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin | Press release | Business Wire | +0.07% | +0.90% | |
| New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters | Press release | Business Wire | — | -0.08% | |
| Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials | Press release | Business Wire | -0.07% | +0.29% | |
| Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming | Press release | Business Wire | -0.12% | -1.11% | |
| The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials | Press release | Business Wire | +0.06% | -1.30% | |
| Luke Bryan and One A Day® Launch Limited Edition Multivitamin Bottles Available Only at Walmart | Press release | Business Wire | -0.13% | +1.30% | |
| Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon | Press release | Business Wire | -0.13% | +1.30% | |
| Bayer and Iambic Collaborate to Advance Drug Discovery with AI | Press release | Business Wire | +0.00% | +1.50% | |
| Bayer Welcomes Kacy Perry as New Country Division Head for Crop Science Canada | Press release | Business Wire | -0.09% | -0.15% | |
| Bayer Completes Acquisition of Perfuse Therapeutics | Press release | Business Wire | -0.14% | -0.14% | |
| Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief | Press release | Business Wire | +0.08% | +0.51% | |
| Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions | Press release | Business Wire | +0.29% | -0.57% | |
| Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business | Press release | Business Wire | +0.39% | -0.29% | |
| Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth | Press release | Business Wire | +0.39% | -0.39% | |
| Phase III FIND-CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non-Diabetic Chronic Kidney Disease | Press release | Business Wire | +0.14% | -0.96% | |
| Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026 | Press release | Business Wire | -0.21% | +1.75% | |
| ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial | Press release | Business Wire | -0.49% | -0.78% | |
| ASCO 2026: Bayer to Present New Data Across Oncology Portfolio | Press release | Business Wire | -0.45% | +1.17% | |
| Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease | Press release | Business Wire | -0.45% | +1.17% | |
| Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack | Press release | Business Wire | +0.23% | -0.04% | |
| U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer | Press release | Business Wire | +0.00% | +1.29% | |
| AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer | Press release | Business Wire | +0.00% | -0.46% | |
| Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement | Press release | Business Wire | -0.27% | -1.63% | |
| Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities | Press release | Business Wire | +0.36% | +0.73% | |
| Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis | Press release | Business Wire | -0.41% | -2.03% | |
| Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline | Press release | Business Wire | +0.29% | +0.11% | |
| Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian | Press release | Business Wire | +0.38% | -0.28% | |
| New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing | Press release | Business Wire | +0.38% | -0.28% | |
| Bayer Canada Supports New School of Medicine at Simon Fraser University (SFU) With Full Tuition Entrance Award for Inaugural Class | Press release | Business Wire | -0.04% | -1.67% | |
| Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential | Press release | Business Wire | -0.09% | +1.95% | |
| Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative | Press release | Business Wire | -0.18% | -0.36% | |
| Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris | Press release | Business Wire | -0.36% | -0.18% | |
| Bayer Crop Science Launches 2026 Opportunity Scholarship Program | Press release | Business Wire | -0.31% | +0.57% | |
| KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease | Press release | Business Wire | -0.26% | -0.26% | |
| New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments | Press release | Business Wire | +0.00% | +4.36% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BAYRY section they belong to.
Where else BAYRY is measured.
BAYRY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Mesoblast Limited - American Depositary Shares (MESO) | 108 | -0.47% | 42% |
| WELLNESS CENTER USA INC (WCUI) | 108 | 0.00% | 24% |
| Aileron Therapeutics, Inc. (ALRN) | 105 | 0.00% | 35% |
| CBA FLORIDA (CBAI) | 105 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BAYER AG S/ADR's median reaction calculated?
Every labeled BAYRY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 106 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of BAYRY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BAYRY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.